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S U M M A R Y
We describe two patients who developed gastrointestinal bleeding due to cytomegalovirus (CMV) colitis
after placement of a HeartMate II left ventricular assist device (LVAD). We aim to raise awareness of CMV
colitis as a possible cause of gastrointestinal bleeding after LVAD placement and discuss potential
mechanisms for CMV reactivation and areas for future research.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Cytomegalovirus (CMV) is one of the most common viral
pathogens, with established latent infection in humans and an
estimated seroprevalence of 60–70% in the general population.1
CMV has long been recognized as the most common opportunistic
infection in immunocompromised patients, with accumulating
evidence of CMV reactivation in up to 36% of critically ill
non-immunosuppressed patients.2 Risk factors for CMV reactiva-
tion in these patients include: male gender, positive CMV IgG,
enteral feeding, prolonged intensive care unit (ICU) stay, blood
transfusions during ICU stay, severe sepsis or septic shock, and
high acute physiology and chronic health evaluation (APACHE II)
scores.2,3
Left ventricular assist devices (LVADs) have become a frequent
alternative for patients with end-stage systolic heart failure
as a bridge to heart transplantation or destination therapy.* Corresponding author. Tel.: +1 402 559 8664; fax: +1 402 553 5527.
E-mail addresses: usandkovsky@unmc.edu, urielsanko@yahoo.com
(U. Sandkovsky).
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bleeding, infections involving the pump, driveline, or pocket,
thrombosis, and renal failure.4 LVAD recipients may have several
risk factors to reactivate CMV. A literature search showed three
reports of CMV-related lower gastrointestinal (GI) tract disease
with different devices (Table 1).5–7 We present the ﬁrst two cases
of CMV colitis that occurred in patients who underwent Heart-
Mate II (HM-II) LVAD placement and discuss possible pathophys-
iological mechanisms for CMV reactivation.
2. Case reports
2.1. Case 1
A 64-year-old man with ischemic cardiomyopathy, end-stage
heart failure, and gout, who had required multiple previous
courses of steroids despite allopurinol maintenance, underwent
placement of an HM-II LVAD. He required 5 days of oral
dexamethasone 4 mg a day for acute gout exacerbation 12 days
after surgery. Three days later, he developed hematochezia and his
hemoglobin dropped to 10.3 g/dl, requiring transfusion of 2 units
of irradiated red blood cells. Colonoscopy showed a friable cecalses. Published by Elsevier Ltd. All rights reserved.
Table 1
Cases of CMV reactivation in the lower gastrointestinal tract after LVAD
Reference Device Risk factors Clinical presentation Labs/cultures; pathology/cultures Management/outcome
Aleksic et al.5 HeartMate 10001
(pulsatile)
Critical illness, ICU,
prolonged hospital stay,
unclear CMV serostatus
Persistent GI bleeding;
ileitis/enteritis, 27 days
post-LVAD
No initial serology or PCR;
pathology showed ileitis and
positive CMV stains
Ileal resection, 14 days
ganciclovir followed by
acyclovir for 3 months
Huttner et al.6 Incor1 (axial ﬂow) Male, critical illness, ICU,
prolonged hospital stay,
CMV IgG-positive
Pneumonitis and ileitis,
53 days post-LVAD
Positive CMV PCR from pleural
ﬂuid; negative cultures (blood
and lung); pathology: lung
showed necrotizing pneumonia,
inclusion bodies and positive
CMV stains and ileitis with
positive CMV stains
Death
Pfau and Rothstein7 Unspeciﬁed Male, critical illness, ICU,
prolonged hospital stay,
positive CMV IgG
Lower GI bleeding;
cecal ulcer
Biopsy of cecal ulcer with acute
inﬂammatory exudate and
intranuclear inclusion
Ganciclovir  21 days,
no recurrence
Sandkovsky et al. HeartMate II1
(axial ﬂow)
Male, steroids, positive
CMV IgG
Patient 1: lower GI
bleeding, necrosis of
the cecum
Blood CMV PCR-negative; no
cultures; pathology: mucosal
ulceration, distorted architecture,
acute and chronic inﬂammation;
CMV stains positive
Right hemicolectomy
and ganciclovir  28
days; no recurrence
HeartMate II1
(axial ﬂow)
Male, enteral feeding,
blood transfusions,
positive CMV IgG
Patient 2: lower GI
bleeding, proctocolitis
Blood CMV PCR 770 copies/ml;
acute and chronic inﬂammation
of the rectosigmoid colon and
ileocecal valve; CMV stains positive
Right hemicolectomy and
ganciclovir  28 days;
no recurrence
CMV, cytomegalovirus; ICU, intensive care unit; IgG, immunoglobulin G; GI, gastrointestinal; LVAD, left ventricular assist device; PCR, polymerase chain reaction.
Figure 1. (a) Ulcerated mucosal surface of the colon containing stromal cells with
eosinophilic intra-nuclear inclusions (black arrow) giving an ‘owl’s eye’ appearance
consistent with cytomegalovirus (CMV) infection (hematoxylin and eosin, 400).
(b) Immunoperoxidase staining for CMV demonstrated the presence of numerous
infected cells within the ulcerated mucosal surface of the colon (200).
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colitis. Failure of medical therapy prompted surgical intervention
with a right hemicolectomy 3 days later. Histopathology revealed
an ulcerated colonic mucosa, distorted architecture, and acute
and chronic inﬂammation. Immunohistochemistry staining was
positive for CMV, and viral inclusions were seen in retrospect
with hematoxylin and eosin stain (Figure 1). CMV by PCR in
blood was negative. Previous CMV IgG was positive. He received a
14-day induction therapy with intravenous ganciclovir 5 mg/kg
every 12 h for 10 days and valganciclovir 900 mg twice daily
for 4 days; then valganciclovir was changed to 450 mg daily
to complete 28 days of maintenance therapy. No recurrence
of CMV colitis or lower GI bleeding was seen after 8 months of
follow-up.
2.2. Case 2
A 71-year-old man with non-ischemic dilated cardiomyopathy
and end-stage heart failure underwent HM-II LVAD placement,
aortic valve repair, and tricuspid valve annuloplasty. His course
was complicated by respiratory failure, shock, ischemic hepatitis,
renal failure, and hemorrhagic cystitis, requiring mechanical
ventilation, vasopressor support, and hemodialysis. He developed
lower GI bleeding that required multiple red blood cell transfu-
sions. A lower endoscopy showed ulceration of the ileocecal valve,
transverse colon, and a 10 mm ulcer in the recto-sigmoid colon.
Because of persistent bleeding and the need to anticoagulate for
LVAD, a right hemicolectomy was performed on post-operative
day 32. Histopathology from the endoscopy and the resected
hemicolon specimens showed an acute inﬂammatory inﬁltrate of
the recto-sigmoid and ileocecal valve, with ulceration and
positive immunohistochemistry staining for CMV; in retrospect
hematoxylin and eosin stain showed cells with possible viral
inclusions (Figure 2); stains for other pathogens (fungal and acid-
fast bacilli) were negative. Blood CMV by PCR was 770 copies/ml.
The patient’s CMV IgG was positive previous to LVAD placement.
He received a 14-day induction with intravenous ganciclovir
5 mg/kg per day (350 mg a day adjusted to kidney function), then
switched to oral valganciclovir 450 mg daily for 28 days
maintenance therapy. He has not had recurrent bleeding episodes
after 6 months.
Figure 2. (a) Ulcerated mucosal surface of the colon containing stromal cells with eosinophilic intra-nuclear inclusions (black arrow) consistent with cytomegalovirus (CMV)
infection (hematoxylin and eosin, 400). (b) Immunoperoxidase staining for CMV demonstrated the presence of multiple infected cells within the ulcerated mucosal surface
of the colon (200).
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Here we underscore a potentially important infectious compli-
cation in LVAD recipients. Complications after LVAD placement are
common4 and GI bleeding is one of the most common and well-
described complications, occurring in a ﬁfth of patients.4,8–10
Interestingly, there has been a signiﬁcant increase in GI bleeding
episodes related to HM-II LVAD compared to HM-I LVAD
placement.8 The lower GI tract is most commonly affected, and
most series have been retrospective and have not included
histopathology descriptions.9,10 Excluding ischemia, at least two
pathophysiological mechanisms may explain the increase in GI
bleeding: ﬁrst the formation of angiodysplasias in the small bowel,
a similar mechanism to the one described in the setting of aortic
stenosis; and second, the development of acquired von Willebrand
disease type 2A, which is most likely caused by shear stress on red
blood cells ﬂowing through the LVAD pump.8–10 We conjecture
that CMV reactivation in the lower GI tract, especially in the
terminal ileum or colon, may be another potential cause of
bleeding. In fact, there are data to support more severe colitis and
bleeding in mice with latent murine CMV infection in the gut.11 On
the other hand, CMV reactivation is well described in patients with
inﬂammatory bowel disease, so it is possible that viral reactivation
in our patients might have occurred in a similar fashion.12,13
It may be worth exploring if LVAD recipients reactivate CMV at a
similar rate to critically ill non-immunosuppressed patients. CMV
reactivation may be self-limited and resolve after a few weeks, but it
is worth considering given its association with increased all-cause
mortality, prolonged ventilator support, and high rates of nosoco-
mial infections.2,3 A summary of the previously reported cases in theliterature with a comparison to our cases is provided in Table 1.5–7
The underlying mechanism of CMV reactivation in critically ill
patients is probably related to dysfunction of the cellular immune
system, with shifting of Th1 to Th2 responses, or even immune
paralysis.2,3 Data suggest that LVAD placement may lead to immune
dysfunction. One proposed mechanism is through lymphopenia
after LVAD implantation, with selective loss of Th1 cytokine-
producing CD4 lymphocytes through apoptosis and concomitant
activation of Th2 CD4 T-cells and B-cell hyper-reactivity.14–16
One of the limitations of our report is the scarce literature on
CMV reactivation in patients undergoing LVAD implantation.
However, we raise several important questions, including poten-
tial areas for future research: (1) Is it worth looking for CMV
reactivation in patients who undergo LVAD placement? If so, when
would be the best time to look? If we hypothesize that CMV
reactivation in LVAD recipients is as common as in non-
immunosuppressed patients admitted to the ICU, susceptibility
to CMV reactivation should be higher in the early period after
device placement while patients are in the ICU, receive blood
transfusions, undergo multiple procedures, or have APACHE scores
>20.2 (2) Should we monitor CMV viremia in every patient, just
selected patients, or do no monitoring at all? How often should we
monitor and what would be the cost associated with CMV by PCR,
which may range between US$ 120 and 150, depending on the
center. (3) Because gastrointestinal bleeding is a common
complication we could easily be overlooking many cases of CMV
colitis. Since most patients would undergo a colonoscopy to
explore the source of bleeding, looking for CMV would not be a
difﬁcult task. Direct visualization would be key to obtaining
biopsies of suspicious tissue or ulcers for proper histopathological
U. Sandkovsky et al. / International Journal of Infectious Diseases 17 (2013) e348–e351 e351analysis. On the other hand, would it be useful to look for CMV in
patients who are CMV IgG-negative? (4) Which non-immunosup-
pressed patients with CMV reactivation need treatment? It is likely
that there will be agreement to treat patients with established
colitis, but what about patients with transient CMV viremia? What
viral load threshold should we look at since end-organ disease like
colitis may either present with low-level or even absence of
viremia, as was the case in our patients. Should high-risk patients
receive prophylaxis? Ultimately, we have to consider that the
indiscriminate treatment of CMV would expose patients to
potentially toxic medications with substantial side effects, not
to mention the high cost of antiviral therapy.
We believe that this is an area deﬁnitely worth exploring. A
well-designed multicenter prospective cohort study could help us
to understand whether and how often CMV reactivation and
disease occurs in patients who undergo LVAD implantation.
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